Smoking does not Alter the Therapy Response to Systemic Anti-psoriatic Therapies: A Two-country, Multi-centre, Prospective, Non-interventional Study
Psoriasis can involve the skin, joints, nails and cardiovascular system and result in a significant impairment in quality of life. Studies have shown a lower response rate to systemic anti-psoriatic therapies in smokers, and smoking is a trigger factor for psoriasis. The aim of this study was theref...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Society for Publication of Acta Dermato-Venereologica
2019-06-01
|
Series: | Acta Dermato-Venereologica |
Subjects: | |
Online Access: |
https://www.medicaljournals.se/acta/content/html/10.2340/00015555-3221
|
id |
doaj-45c38210af8147dc9c6f635f1d76ae11 |
---|---|
record_format |
Article |
spelling |
doaj-45c38210af8147dc9c6f635f1d76ae112020-11-25T01:40:09ZengSociety for Publication of Acta Dermato-VenereologicaActa Dermato-Venereologica0001-55551651-20572019-06-01991087187710.2340/00015555-32215488Smoking does not Alter the Therapy Response to Systemic Anti-psoriatic Therapies: A Two-country, Multi-centre, Prospective, Non-interventional StudyFlorian Anzengruber0Matthias AugustinMarc A. RadtkeDiamant ThaciNikhil YawalkarMarkus StreitKristian ReichMathias DrachChristina SorbeLars E. FrenchUlrich MrowietzJulia-Tatjana MaulPeter H. ItinAlexander A. Navarini Department of Dermatology, University Hospital Zurich, 8091 Zurich, Switzerland. Psoriasis can involve the skin, joints, nails and cardiovascular system and result in a significant impairment in quality of life. Studies have shown a lower response rate to systemic anti-psoriatic therapies in smokers, and smoking is a trigger factor for psoriasis. The aim of this study was therefore to analyse the response to systemic therapies for psoriasis, with a focus on smoking. Prospectively collected data from patients with moderate to severe psoriasis included in the national psoriasis registries for Germany and Switzerland (PsoBest and SDNTT) were analysed. Therapy response was defined as reaching a Psoriasis Area and Severity Index (PASI) reduction of 75%, PASI ≤ 3 or Dermatology Life Quality Index (DLQI) ≤ 1. Out of 5,346 patients included in these registries, 1,264 met the inclusion criteria for this study. In the smoking group, 715 (60.6%) reached therapy response at month 3, compared with 358 (63.7%) in the non-smoking group (p ≤ 0.269), 659 (74.1%) vs. 330 (77%) reached therapy response at month 6 (p ≤ 0.097), and 504 (76.6%) vs. 272 (79.0%) at month 12 (p ≤ 0.611). Therefore, these data do not show that smoking affects the response rate of anti-psoriatic therapy after 3, 6 and 12 months. https://www.medicaljournals.se/acta/content/html/10.2340/00015555-3221 tobacco nicotine psoriasis fumaric acid esters methotrexate acitretin ciclosporin apremilast adalimumab etanercept infliximab ustekinumab secukinumab treatment response |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Florian Anzengruber Matthias Augustin Marc A. Radtke Diamant Thaci Nikhil Yawalkar Markus Streit Kristian Reich Mathias Drach Christina Sorbe Lars E. French Ulrich Mrowietz Julia-Tatjana Maul Peter H. Itin Alexander A. Navarini |
spellingShingle |
Florian Anzengruber Matthias Augustin Marc A. Radtke Diamant Thaci Nikhil Yawalkar Markus Streit Kristian Reich Mathias Drach Christina Sorbe Lars E. French Ulrich Mrowietz Julia-Tatjana Maul Peter H. Itin Alexander A. Navarini Smoking does not Alter the Therapy Response to Systemic Anti-psoriatic Therapies: A Two-country, Multi-centre, Prospective, Non-interventional Study Acta Dermato-Venereologica tobacco nicotine psoriasis fumaric acid esters methotrexate acitretin ciclosporin apremilast adalimumab etanercept infliximab ustekinumab secukinumab treatment response |
author_facet |
Florian Anzengruber Matthias Augustin Marc A. Radtke Diamant Thaci Nikhil Yawalkar Markus Streit Kristian Reich Mathias Drach Christina Sorbe Lars E. French Ulrich Mrowietz Julia-Tatjana Maul Peter H. Itin Alexander A. Navarini |
author_sort |
Florian Anzengruber |
title |
Smoking does not Alter the Therapy Response to Systemic Anti-psoriatic Therapies: A Two-country, Multi-centre, Prospective, Non-interventional Study |
title_short |
Smoking does not Alter the Therapy Response to Systemic Anti-psoriatic Therapies: A Two-country, Multi-centre, Prospective, Non-interventional Study |
title_full |
Smoking does not Alter the Therapy Response to Systemic Anti-psoriatic Therapies: A Two-country, Multi-centre, Prospective, Non-interventional Study |
title_fullStr |
Smoking does not Alter the Therapy Response to Systemic Anti-psoriatic Therapies: A Two-country, Multi-centre, Prospective, Non-interventional Study |
title_full_unstemmed |
Smoking does not Alter the Therapy Response to Systemic Anti-psoriatic Therapies: A Two-country, Multi-centre, Prospective, Non-interventional Study |
title_sort |
smoking does not alter the therapy response to systemic anti-psoriatic therapies: a two-country, multi-centre, prospective, non-interventional study |
publisher |
Society for Publication of Acta Dermato-Venereologica |
series |
Acta Dermato-Venereologica |
issn |
0001-5555 1651-2057 |
publishDate |
2019-06-01 |
description |
Psoriasis can involve the skin, joints, nails and cardiovascular system and result in a significant impairment in quality of life. Studies have shown a lower response rate to systemic anti-psoriatic therapies in smokers, and smoking is a trigger factor for psoriasis. The aim of this study was therefore to analyse the response to systemic therapies for psoriasis, with a focus on smoking. Prospectively collected data from patients with moderate to severe psoriasis included in the national psoriasis registries for Germany and Switzerland (PsoBest and SDNTT) were analysed. Therapy response was defined as reaching a Psoriasis Area and Severity Index (PASI) reduction of 75%, PASI ≤ 3 or Dermatology Life Quality Index (DLQI) ≤ 1. Out of 5,346 patients included in these registries, 1,264 met the inclusion criteria for this study. In the smoking group, 715 (60.6%) reached therapy response at month 3, compared with 358 (63.7%) in the non-smoking group (p ≤ 0.269), 659 (74.1%) vs. 330 (77%) reached therapy response at month 6 (p ≤ 0.097), and 504 (76.6%) vs. 272 (79.0%) at month 12 (p ≤ 0.611). Therefore, these data do not show that smoking affects the response rate of anti-psoriatic therapy after 3, 6 and 12 months. |
topic |
tobacco nicotine psoriasis fumaric acid esters methotrexate acitretin ciclosporin apremilast adalimumab etanercept infliximab ustekinumab secukinumab treatment response |
url |
https://www.medicaljournals.se/acta/content/html/10.2340/00015555-3221
|
work_keys_str_mv |
AT floriananzengruber smokingdoesnotalterthetherapyresponsetosystemicantipsoriatictherapiesatwocountrymulticentreprospectivenoninterventionalstudy AT matthiasaugustin smokingdoesnotalterthetherapyresponsetosystemicantipsoriatictherapiesatwocountrymulticentreprospectivenoninterventionalstudy AT marcaradtke smokingdoesnotalterthetherapyresponsetosystemicantipsoriatictherapiesatwocountrymulticentreprospectivenoninterventionalstudy AT diamantthaci smokingdoesnotalterthetherapyresponsetosystemicantipsoriatictherapiesatwocountrymulticentreprospectivenoninterventionalstudy AT nikhilyawalkar smokingdoesnotalterthetherapyresponsetosystemicantipsoriatictherapiesatwocountrymulticentreprospectivenoninterventionalstudy AT markusstreit smokingdoesnotalterthetherapyresponsetosystemicantipsoriatictherapiesatwocountrymulticentreprospectivenoninterventionalstudy AT kristianreich smokingdoesnotalterthetherapyresponsetosystemicantipsoriatictherapiesatwocountrymulticentreprospectivenoninterventionalstudy AT mathiasdrach smokingdoesnotalterthetherapyresponsetosystemicantipsoriatictherapiesatwocountrymulticentreprospectivenoninterventionalstudy AT christinasorbe smokingdoesnotalterthetherapyresponsetosystemicantipsoriatictherapiesatwocountrymulticentreprospectivenoninterventionalstudy AT larsefrench smokingdoesnotalterthetherapyresponsetosystemicantipsoriatictherapiesatwocountrymulticentreprospectivenoninterventionalstudy AT ulrichmrowietz smokingdoesnotalterthetherapyresponsetosystemicantipsoriatictherapiesatwocountrymulticentreprospectivenoninterventionalstudy AT juliatatjanamaul smokingdoesnotalterthetherapyresponsetosystemicantipsoriatictherapiesatwocountrymulticentreprospectivenoninterventionalstudy AT peterhitin smokingdoesnotalterthetherapyresponsetosystemicantipsoriatictherapiesatwocountrymulticentreprospectivenoninterventionalstudy AT alexanderanavarini smokingdoesnotalterthetherapyresponsetosystemicantipsoriatictherapiesatwocountrymulticentreprospectivenoninterventionalstudy |
_version_ |
1725046815501320192 |